Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA Approves Truseltiq (infigratinib) for the Treatment of Cholangiocarcinoma

drugsMay 31, 2021

Tag: cholangiocarcinoma , Truseltiq , FGFR2

PharmaSources Customer Service